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ﬁstulas reconstructed by vascular stripping in
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Fang-Ping Lu, MD, Li-Ping Liu, MD, and Zhao-Xuan Lu, MD, Beijing, China
Objective: There are limited therapeutic measures for stenosis of arteriovenous ﬁstulas (AVFs) due to venous neointimal
hyperplasia (VNH). In the current retrospective study, we reviewed the clinical data of hemodialysis patients who un-
derwent AVF reconstruction by VNH stripping. The primary measure of interest was the secondary patency rate of the
restored AVF.
Methods: The study included hemodialysis patients who underwent AVF reconstruction by VNH stripping (group A),
AVF reconstruction proximal to the original ﬁstula (group B), or creation of a new AVF (group C). Patency was evaluated
immediately after the surgery and at follow-up visits.
Results: Of 353 patients who underwent AVF reconstructions, 327 (91.9%) were for late AVF failure. The ﬁnal analysis
included 305 patients: 76, 128, and 101 patients in groups A, B, and C, respectively. The three groups were comparable
in age, sex, causes for AVF, AVF sites, and the artery for the AVF (P > .05). At 3-month follow-up, the secondary AVF
patency rate was comparable across the three groups at 93.4%, 92.2%, and 92.1% in groups A, B, and C, respectively. The
patency rate at 6 and 12 months was also comparable across groups A, B, and C at 89.5%, 89.8%, and 88.1% at 6 months
and 84.2%, 85.9%, and 81.2% at 12 months, respectively.
Conclusions: Reconstructing the AVF by surgically removing VNH is an effective technique for late hemodialysis access
failure, with maximal preservation of blood vessels. (J Vasc Surg 2015;61:192-6.)A native arteriovenous (AV) ﬁstula (AVF) is the
preferred choice for permanent hemodialysis because of
the low incidence of infection and thrombosis and high
long-term patency.1 However, a mature AVF may still
develop venous neointimal hyperplasia (VNH) after a
period of successful use, leading to venous stenosis with
or without thrombosis. Failure of an AVF vascular access
can be early (failed maturation of AV anastomosis, typically
in <3 months after AVF creation) or late (>3 months after
AVF creation).2 The most important factor causing late
failure is venous stenosis, particularly perianastomotic stric-
ture due to VNH formation.
In most patients, VNH is managed with percutaneous
transluminal angioplasty (PTA). However, PTA itself can
induce vascular injury, myoﬁbroblast migration and prolif-
eration, and abnormal vascular remodeling, and conse-
quently, relapsed AVF stricture.3,4 A new AV anastomosis
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We recently developed an operative technique to repair
AVFs by surgical stripping of VNH and AV reanastomo-
sis.5 In the current retrospective study, we reviewed the
clinical data of hemodialysis patients who had undergone
AVF reconstruction by VNH stripping. The primary inter-
est of the analysis was the secondary patency rate of
restored AVF.
METHODS
The Institutional Review Board of First Hospital of
Tsinghua University, Beijing, China, approved the study
protocol.
Patients. The current study included all hemodialysis
patients who underwent AVF reconstruction by VNH
stripping between January 2007 and December 2011 at
the First Hospital of Tsinghua University. The criteria for
inclusion in the analysis were forearm or upper arm AVF
access with the anastomosis performed below the elbow
and late (>3 months after AVF establishment) AVF failure
or dysfunction (hemodialysis blood ﬂow of <200 mL/
min). The analysis excluded patients with early AVF access
failure or dysfunction (<3 months after AVF establish-
ment), upper arm (anastomosis created above the elbow)
AVF, AVF grafts, or death or loss to follow-up. Patient
consent was not required because of the retrospective na-
ture of this study.
The surgical technique. All patients provided written
informed consent for the treatment before surgery. The
Fig 1. Stripping of venous neointimal hyperplasia (VNH) is done
with forceps down-folding the normal surrounding vascular wall
like “taking off socks.”
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(group A), AVF reconstruction proximal to the original ﬁs-
tula (group B), and creation of a new AVF (group C). Se-
lection of the protocol was based on physician discretion.
Major indications for AVF reconstruction by VNH strip-
ping were:
1. Paraanastomotic VNH or venous stenosis, or both,
in an AVF at any location in the forearm, including
a radial-cephalic or ulnar-basilic ﬁstula;
2. Sufﬁcient vein for cannulation in the forearm and up-
per arm;
3. Blood ﬂow during hemodialysis at <200 mL/min in
the absence of thrombus or <300 mL/min if pa-
tients required high-ﬂux dialysis or hemodiaﬁltration
therapy while other interventions were unsuccessful;
4. #7 days after complete ﬁstula occlusion by
thrombus.
Contraindications were proximal venous (including the
central vein) or arterial stenosis, or both, in the forearm.
The same surgeon performed all three types of opera-
tion. The AVF was established in an end-to-side pattern. A
newly created or reconstructed AVF proximal to the previ-
ous ﬁstula, with or without resection of the occluded vein,
was made according to the standard protocols for ﬁstula
construction.6 VNH stripping was performed as previously
described.5 Brieﬂy, patients were placed supine or sitting
with the operated-on arm laterally rotated and abducted.
Blood vessels were marked using a Sharpie pen (Newell
Rubbermaid, Downers Grove, Ill), or methyl violet.
After disinfection and local anesthesia with 1% lido-
caine, a transverse incision was made proximal to the orig-
inal anastomosis and a preferable 3-cm segment of the
venous end (cephalic or basilic) was dissected for reaching
and reanastomosis with the artery. Venous thrombus, if
present, was removed, and t6he vein was ﬂushed using a
10-mL syringe connected to a noninvasive needle and byinjecting 20 to 50 mL heparinized saline into the vascular
lumen. VNH was then carefully stripped with forceps,
down-folding the normal surrounding vascular wall like
“taking off socks” (Fig 1). The artery was dissected, and
ﬁnally, an end-to-side AV anastomosis was made using a
7-0 vascular suture.
Follow-up study. AVF patency was evaluated imme-
diately, 1 day, and 2 weeks after the procedure. Follow-
up was performed at 3-month intervals until 12 months.
The examination included palpating of the thrill, auscul-
tation of the bruit, and assessment of hemodialysis
outcome.
Patency was deﬁned as (1) the presence of ﬁstulous
vascular pulsation and palpable thrill, (2) the presence of
audible continuous vascular murmurs, (3) $200 mL/min
blood ﬂow rate needed for hemodialysis, and (4) no inter-
vention required to maintain patency. Primary patency was
deﬁned as intervention-free access survival from the time of
surgical creation to the ﬁrst access thrombosis or access
salvage procedure aimed at maintaining or re-establishing
patency or to the time of measurement of patency.2 Sec-
ondary patency was deﬁned as the interval from AVF
reconstruction or surgical creation of a new AVF until ac-
cess abandonment or the time patency was measured.
Primary failure was deﬁned as an AVF that did not
develop to maintain dialysis or became thrombosed before
the ﬁrst successful cannulation for hemodialysis treatment.
Secondary failure was deﬁned as permanent failure of the
AVF after it had achieved adequacy for hemodialysis. The
primary outcome of this retrospective study was secondary
patency rates.
Statistical analysis. Data are expressed as mean 6
standard deviation and were analyzed by the Student t-
test using SPSS 10.0 software (SPSS Inc, Chicago, Ill).
Enumeration data were analyzed by c2 test. Patency rate
was analyzed using the Kaplan-Meier method. Data from
patients who died or underwent renal transplantation
during the study period were censored. Statistical signiﬁ-
cance was set at P < .05.
RESULTS
Patient demographic and baseline characteristics.
The study ﬂowchart is shown in Fig 2. Late AVF failure
occurred in 327 of the 353 patients (91.9%) who under-
went an AVF operation. AVF reconstruction was by VNH
stripping (group A) in 76 patients (23.2%), was proximal to
the original ﬁstula (group B) in 128 (39.1%), and a new
AVF (group C) was created in 101 (30.9%). Four patients
in group A were excluded due to death (n ¼ 3) or loss to
follow-up (n ¼ 1), 10 patients in group B were excluded
due to death (n ¼ 4) or loss to follow-up (n ¼ 6), and eight
patients in group C were excluded due to death (n ¼ 3) or
loss to follow-up (n ¼ 5). Consequently, 305 patients were
included in the ﬁnal analysis: 76 in group A, 128 in group
B, and 101 in group C.
The patient demographic and baseline characteristics
are listed in Table I. Patients were a mean age of 57.7 6
15.7 years (range, 20-86 years), and there were slightly
Fig 2. Flowchart of patients in the study. AVF, Arteriovenous ﬁstula; VNH, venous neointimal hyperplasia.
JOURNAL OF VASCULAR SURGERY
194 Lu et al January 2015more women (52.1%) than men (47.9%). Hemodialysis
was required because of diabetic nephropathy in 35.1% of
patients, chronic glomerulonephritis in 27.9%, and hyper-
tensive nephropathy in 26.6%. Most AVF sites were in
the left forearm (70.8%), followed by AVFs in the right
forearm (25.9%). Most AVFs used the radial artery
(93.4%). The differences in age, sex, causes for AVF,
AVF sites, and the artery used for AVF among the three
groups were not statistically signiﬁcant (P > .05; Table II).
Secondary patency rates. The Kaplan-Meier curve of
patency rates is shown in Fig 3. Most patients (93.4%) who
had undergone AVF reconstruction by VNH stripping
maintained AVF patency at 3 months of follow-up, with
the patency rate comparable to, though slightly higher
than, that of patients who had undergone AVF recon-
struction proximal to the original ﬁstula (92.2%) and of
patients with a new AVF (92.1%; P > .05). The patency
rate of AVFs treated with VNH stripping declined to 89.5%
at 6 months and to 84.2% at 1 year after AVF recon-
struction. Similar declines were observed in patency rates of
AVFs proximal to the original ﬁstula (6 months: 89.8%;
12 months: 85.9%) and new AVFs (6 months: 88.1%;2 months: 81.2%). The patency rates at 6 months and
1 year after salvage remained comparable among the three
groups (P > .05).
DISCUSSION
As an effective and safe vascular access, the AVF has
been applied in hemodialysis patients for nearly 50 years.
The notion of “autologous AV ﬁstula ﬁrst” has been pro-
posed by the United States 2006 National Kidney Founda-
tion Kidney Disease Outcomes Quality Initiative (NKF-K/
DOQI) Clinical Practice Guidelines for Vascular Access.
However, with extended survival of hemodialysis patients
and an increasing trend in the morbidities of diabetes, hy-
pertension, and obesity, establishment of AVFs becomes
increasingly difﬁcult, and AVF-associated complications
have also been on the rise. An increase in hospitalization
and treatment costs resulting from ﬁstula failure has been
a great concern for dialysis patients. The development of
venous stenosis likely involves uremia itself, operative tech-
nique, and hemodynamic and pathophysiologic factors.7,8
Major therapeutic approaches for VNH-caused ﬁstu-
lous vascular stricture include (1) PTA and endovascular
Table I. Patient demographic and baseline characteristics
Variables All patients Group A Group B Group C
AVF, No. (%) 305 (100) 76 (24.9) 128 (42.0) 101 (33.1)
Age, years
Mean 6 SD 57.7 6 15.7 59.7 6 12.7 58 6 16.1 55.8 6 17.1
Range 20-86 20-83 22-83 20-86
Male, No. (%) 146 (47.9) 39 (51.3) 61 (47.7) 46 (45.6)
Need for AVF, No. (%)
Chronic glomerulonephritis 85 (27.9) 21 (27.6) 31 (24.2) 33 (32.7)
Diabetic nephropathy 107 (35.1) 29 (38.2) 50 (39.1) 28 (27.7)
Hypertensive nephropathy 81 (26.6) 19 (25.0) 36 (28.1) 26 (25.7)
Drug toxicities 17 (5.6) 3 (3.9) 6 (4.7) 8 (7.9)
Polycystic kidneys 7 (2.3) 2 (2.6) 2 (1.6) 3 (3.0)
Unknown 7 (2.3) 2 (2.6) 3 (2.3) 2 (2.0)
AVF sites, No. (%)
Left forearm 216 (70.8) 54 (71.1) 89 (69.5) 73 (72.3)
Right forearm 79 (25.9) 22 (28.9) 30 (23.4) 27 (26.7)
Right upper arm 4 (1.3) 0 (0.0) 4 (3.1) 0 (0.0)
Left upper arm 6 (2.0) 0 (0.0) 5 (3.9) 1 (1.0)
AVF artery, No. (%)
Radial 285 (93.4) 70 (92.1) 121 (94.5) 94 (93.1)
Ulnar 20 (6.6) 6 (7.9) 7 (5.5) 7 (6.9)
AVF, Arteriovenous ﬁstula; Group A, AVF reconstruction by venous neointimal hyperplasia (VNH) stripping; Group B, AVF reconstruction proximal to the
original ﬁstula; Group C, newly created AVF; SD, standard deviation.
Table II. Patency rates of arteriovenous ﬁstulas (AVFs)
Variables Group A, No. (%) Group B, No. (%) Group C, No. (%) c2 P
Immediately after surgery 76 (100) 128 (100) 101 (100)
Follow-up
2 weeks 76 (100) 128 (100) 101 (100)
3 months 71 (93.4) 118 (92.2) 93 (92.1) 0.125 .935
6 months 68 (89.5) 115 (89.8) 89 (88.1) 0.183 .913
12 months 64 (84.2) 110 (85.9) 82 (81.2) 0.095 .622
Group A, AVF reconstruction by venous neointimal hyperplasia (VNH) stripping; Group B, AVF reconstruction proximal to the original ﬁstula; Group C,
newly created AVF.
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catheter, (3) AV reanastomosis proximal to the narrowed
site, and (4) vascular grafts. Among these techniques,
PTA is the primary choice recommended in the NKF-K/
DOQI guidelines.
Gmelin et al9 ﬁrst introduced PTA to treat ﬁstula ste-
nosis in 1989. Its advantages include safety and efﬁcacy,
less vascular injury, easy surgical operation, and repeatable
ﬁstulous vasodilation at multiple time and locations. In
addition, this procedure is carried out in the original ﬁstula
vessels and does not waste additional native blood vessels,
shortens the time of ﬁstula maturation, and has fewer com-
plications.3 Yet, one of the disadvantages using PTA is the
likelihood of AVF stricture relapse. Tessitore et al10 re-
ported that the incidence of relapsed stricture after PTA
was markedly higher than after surgical ﬁstula reconstruc-
tion (P ¼ .009). Napoli et al11 also demonstrated that sur-
gical treatment for narrow or occluded ﬁstulas resulted in
better initial patency than other approaches.
In contrast to the traditional surgical procedure, which
usually abandons part of the ﬁstulous vessels, we treated 76
hemodialysis patients with late AVF failure by surgical strip-
ping of VNH and successfully preserved the originalﬁstulous vessels. This operation to restore the AVF achieves
a ﬁstula patency rate comparable to that resulting from the
initially created AVF or an AVF reconstructed proximally
to the original ﬁstula, with or without resection of
occluded vein. Thus, this offers an effective alternative
treatment choice for patients with AVF when PTA or
PTA plus stenting are not readily available, such as in
most community hospitals in developing countries.
The restored AVF by VNH stripping can be used for
hemodialysis immediately after the operation, and waiting
for several weeks for ﬁstula maturation is not necessary
because the veins have already arterialized. A little residual
VNH may remain with the procedure but will not affect
the venous lumen and will recover by itself after restoration
of blood ﬂow.
The mechanism by which the ﬁstulous vascular lumen
repairs itself after VNH stripping is unclear, presumably
by endothelial remodeling or re-endothelialization with
the restoration of lumen patency. Pathologic examination
of VNH specimens reveals that there still are endothelial
gaps ﬁlled with CD34 and factor VIII-positive cells be-
tween the vascular wall and the VNH tissue (data not
presented), indicating that residual endothelial cells may
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Fig 3. The Kaplan-Meier curve of patency rates. The numbers at
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lumen after stripping of VNH. Amelioration of uremia
by hemodialysis signiﬁcantly increases the number of
circulating endothelial progenitor cells and improves
endothelial function in end-stage nephropathy.12,13
Thus, restarting dialysis therapy as quickly as possible
may also be beneﬁcial for the reconstructed AVF to be
functional and to restore ﬁstula patency.CONCLUSIONS
We have demonstrated long-term patency rates of AVFs
reconstructed by surgically removing VNH and reanasto-
mosis that are comparable with the patency rates obtained
by other surgical approaches. This procedure provides
maximal preservation of blood vessels for long-term hemo-
dialysis, shortens the time to restart hemodialysis therapyusing the ﬁstula, and can be a substitutive operation
for failed AVFs.
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